Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.
馬薩諸塞州劍橋，2024 年 2 月 28 日（環球新聞專線）— 黑鑽療法有限公司 納斯達克股票代碼：BDTX）是一家開發針對基因定義癌症患者致癌突變家族的MasterKey療法的臨床階段腫瘤公司。該公司今天宣佈，其首席執行官Mark A. Velleca醫學博士將參加美國東部時間2024年3月6日星期三上午9點10分在波士頓舉行的TD Cowen第44屆年度醫療保健會議上關於肺癌的小組討論。MA。
A live webcast of the panel can be accessed by visiting the investor relations section of the Company's website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
該小組的網絡直播可訪問公司網站的投資者關係部分，網址爲： www.blackdiamondther。網絡直播的重播也將在活動結束後的90天內提供和存檔。
About Black Diamond
Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company's MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
關於黑鑽石
Black Diamond Therapeutics是一家臨床階段的腫瘤學公司，專注於開發MasterKey療法，以解決臨床驗證的靶標中的致癌突變家族。該公司的MasterKey療法旨在針對廣泛的基因定義的患者群體，克服耐藥性，最大限度地減少野生型介導的毒性，並具有大腦穿透力來治療中樞神經系統疾病。該公司正在推進兩個臨床階段的項目：BDTX-1535，一種靶向表皮生長因子突變體NSCLC和GBM的第四代表皮生長因子MasterKey抑制劑，以及一種針對實體瘤KRAS、NRAS和BRAF改變的腦穿透性RAF MasterKey抑制劑 BDTX-4933。欲了解更多信息，請訪問 www.blackdiamondther。
Contacts
聯繫人
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
對於投資者：
馬里奧·科爾索，Black Diamond Therapeutics投資者關係主管
mcorso@bdtx.com
For Media:
media@bdtx.com
對於媒體：
media@bdtx.com
譯文內容由第三人軟體翻譯。